IDEAYA Biosciences, Inc.
IDYA
$30.24
$0.391.31%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 78.48% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 78.48% | -- |
| Cost of Revenue | 45.21% | 36.11% | 65.60% | 261.58% | 69.59% |
| Gross Profit | 318.44% | -36.11% | -65.60% | -282.18% | -122.70% |
| SG&A Expenses | 68.25% | 40.27% | 64.43% | 54.97% | 23.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.57% | 36.78% | 65.41% | 229.71% | 60.94% |
| Operating Income | 262.13% | -36.78% | -65.41% | -243.87% | -99.53% |
| Income Before Tax | 330.11% | -46.84% | -82.40% | -283.78% | -88.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 330.11% | -46.84% | -82.40% | -283.78% | -88.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 330.11% | -46.84% | -82.40% | -283.78% | -88.85% |
| EBIT | 262.13% | -36.78% | -65.41% | -243.87% | -99.53% |
| EBITDA | 264.53% | -36.98% | -66.24% | -247.72% | -101.65% |
| EPS Basic | 324.01% | -29.40% | -55.04% | -186.70% | -31.49% |
| Normalized Basic EPS | 324.03% | -29.38% | -55.06% | -152.05% | -31.49% |
| EPS Diluted | 321.19% | -29.40% | -55.04% | -186.70% | -31.49% |
| Normalized Diluted EPS | 321.10% | -29.38% | -55.06% | -152.05% | -31.49% |
| Average Basic Shares Outstanding | 2.71% | 13.48% | 17.64% | 33.86% | 43.65% |
| Average Diluted Shares Outstanding | 4.06% | 13.48% | 17.64% | 33.86% | 43.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |